Teva Denmark A/S
A/SActiveAdvertising protectionCVR 29634076Vandtårnsvej 83A, 2860 SøborgWholesale of pharmaceutical and medical goods· NACE 4646Est. 2006 · 20 years old38 employeeshttps://www.tevapharm.dk
Loading company…
Overview
Teva Denmark A/S is a Danish A/S based in Søborg, operating in the Wholesale of pharmaceutical and medical goods sector. Incorporated in 2006, the company has 38 employees and reported revenue of DKK 645.3m in its latest annual filing.
Revenue 2025
645.3M DKK
+2% vs 2024
EBITDA margin
9.7 %
−21% vs 2024
Net profit 2025
46.8M DKK
-18% vs 2024
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
36.9 %
AverageAround the average of companies in the same industry
20212025
Liquidity ratioCurrent assets ÷ Short-term debt
1.5×
AverageAround the average of companies in the same industry
20212025
Return on assets (ROA)Net profit ÷ Total assets × 100
15.2 %
StrongAmong the 30% highest rated companies in the industry
20212025
EBITDA — year on year
DKK millionsKey figures
Annual report 2025| Revenue | 645.3M DKK | +2% |
| EBITDA | 62.4M DKK | -21% |
| Net profit | 46.8M DKK | -18% |
| Total assets | 308M DKK | -5% |
| Equity | 113.7M DKK | -32% |
| Employees | 38 | — |
Company information
Legal name
TEVA DENMARK A/S
CVR number
29634076
Legal form
Aktieselskab
NACE code
Founded
8 June 2006 · 20 years
Share capital
DKK 501,000
Employees
38 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af (i) to medlemmer af bestyrelsen i forening, (ii) af et medlem af bestyrelsen sammen med et medlem af direktionen, (iii) af to direktører i forening eller (iv) af den samlede bestyrelse.
Company purpose
Selskabets formål er : (a) at importere/eksportere, registrere, markedsføre og distribuere lægemidler og relaterede produkter til brug for mennesker eller dyr, (b) at stifte, have andel i, administrere, rådgive, auditere, samarbejde med, forestå ledelsen af og yde tjenester til andre selskaber og virksomheder, samt finansiere andre selskaber og virksomheder, og (c) at udføre enhver aktivitet, som måtte være relateret til eller befordrende for ovenstående i bredest mulige forstand. Selskabet kan stille sikkerhed, pantsætte aktiver, garantere for opfyldelsen af samt forpligte sig særskilt eller på anden vis for betalingen af koncernselskabers og/eller tredjemands gæld.
(no translation available)
Contact
Address
Vandtårnsvej 83A, 2860 Søborg
Phone
+45 4498 5511
Email
info@tevapharm.dk
Website
https://www.tevapharm.dk
Advertising protection
Active — opted out of marketing use
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2025), Teva Denmark A/S reported revenue of DKK 645.3m, an increase of 2% on the year before. The figures on this page draw on 5 annual filings covering 2021 to 2025. The bottom line showed a net profit of DKK 46.8m, and the EBITDA margin stood at 9.7%.
At the end of 2025, equity financed 36.9% of the balance sheet, and current assets covered short-term debt 1.5 times.
Financials
Revenue
DKK millionsEBITDA
DKK millionsIncome statement
DKK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 645,331 | 632,169 | 517,926 | 411,374 | 384,312 |
| Staff expenses | -39,709 | -37,257 | -31,869 | -32,695 | -32,658 |
| EBITDA | 62,408 | 78,592 | 68,979 | 53,616 | 57,164 |
| Depreciation & amort. | -50 | -5,020 | -11,315 | -14,338 | -16,155 |
| EBIT | 62,358 | 73,572 | 57,664 | 39,278 | 41,009 |
| Net financials | -946 | 1,801 | 2,661 | 15,120 | -176 |
| Profit before tax | 61,412 | 75,373 | 60,325 | 54,398 | 40,833 |
| Tax | 14,595 | 17,951 | 13,622 | 13,164 | 10,310 |
| Net profit | 46,817 | 57,422 | 46,703 | 41,234 | 30,523 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
DKK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 308,044 | 325,745 | 376,225 | 274,911 | 296,657 |
| Equity | 113,670 | 166,853 | 209,431 | 199,728 | 173,176 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 194,374 | 158,892 | 166,794 | 75,183 | 123,481 |
| Total debt | 194,374 | 158,892 | 166,794 | 75,183 | 123,481 |
Financial ratios
5-year trendEBITDA margin
9.7 %
20212025
Equity ratio
36.9 %
AverageAround the average of companies in the same industry
20212025
Return on equity
41.2 %
StrongAmong the 30% highest rated companies in the industry
20212025
Net profit margin
7.3 %
StrongAmong the 30% highest rated companies in the industry
20212025
Asset turnover
2.09×
StrongAmong the 40% highest rated companies in the industry
20212025
Debt / equity
1.71×
WeakAmong the 40% lowest rated companies in the industry
20212025
Sector performance
28 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Gross marginWeak
Among the 40% lowest rated companies in the industry
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginVery strong
Among the 20% highest rated companies in the industry
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginStrong
Among the 30% highest rated companies in the industry
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Return on equity (ROE)Strong
Among the 30% highest rated companies in the industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Strong
Among the 30% highest rated companies in the industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Strong
Among the 30% highest rated companies in the industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Very strong
Among the 20% highest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Capacity ratioVery strong
Among the 10% highest rated companies in the industry
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Liquidity
Current ratioAverage
Around the average of companies in the same industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioWeak
Among the 40% lowest rated companies in the industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioVery weak
Among the 10% lowest rated companies in the industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Current assets to equityWeak
Among the 40% lowest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalAverage
Around the average of companies in the same industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioStrong
Among the 40% highest rated companies in the industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Debt & solvency
Solidity ratioAverage
Around the average of companies in the same industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioAverage
Around the average of companies in the same industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityWeak
Among the 40% lowest rated companies in the industry
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityWeak
Among the 40% lowest rated companies in the industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Income to debtStrong
Among the 30% highest rated companies in the industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtStrong
Among the 30% highest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageVery strong
Among the 20% highest rated companies in the industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtStrong
Among the 40% highest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginStrong
Among the 30% highest rated companies in the industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Efficiency & development
Asset turnoverStrong
Among the 40% highest rated companies in the industry
Revenue relative to total assets — the ability to generate revenue from the asset base.
Inventory turnoverStrong
Among the 30% highest rated companies in the industry
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Equity to contributed capitalVery strong
Among the 10% highest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityVery weak
Among the 20% lowest rated companies in the industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtWeak
Among the 30% lowest rated companies in the industry
The size of this year's increase or decrease in the company's debt.
Annual reports & filings
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
BP Management | Management | 2018 |
MN Chief Executive Officer | Chief Executive Officer | 2019 |
Former (8)
PM Chief Executive Officer | Chief Executive Officer | 2012 – 2014 |
EG Management | Management | 2010 – 2011 |
SJ Management | Management | 2006 – 2010 |
LJ Management | Management | 2008 – 2010 |
KV Management | Management | 2014 – 2016 |
AO Management | Management | 2016 – 2018 |
TJ Management | Management | 2010 – 2011 |
BL Management | Management | 2014 – 2017 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
MV Board of Directors | Board of Directors | 2019 |
HG Board of Directors | Board of Directors | 2018 |
MN Board of Directors | Board of Directors | 2017 |
Former (13)
PM Chairman | Chairman | 2014 – 2015 |
EG Board of Directors | Board of Directors | 2011 – 2012 |
HP Chairman | Chairman | 2018 – 2020 |
SJ Board of Directors | Board of Directors | 2006 – 2010 |
LJ Board of Directors | Board of Directors | 2011 – 2012 |
KV Board of Directors | Board of Directors | 2012 – 2014 |
TO Board of Directors | Board of Directors | 2014 – 2016 |
OT Chairman | Chairman | 2016 – 2018 |
GN Board of Directors | Board of Directors | 2014 – 2014 |
JA Chairman | Chairman | 2006 – 2010 |
BN Board of Directors | Board of Directors | 2016 – 2019 |
TJ Chairman | Chairman | 2014 – 2014 |
BL Board of Directors | Board of Directors | 2013 – 2017 |
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
Teva Pharma B.V. | Company | 100% | 100% | 2012 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
Teva Pharma B.V.100%
Teva Denmark A/S (this company)Board network connections
Board members of Teva Denmark A/S also hold positions in 4 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lone Juul Darket | Management | 2 companies |
| Kim Vallentin Peetz | Management | 1 company |
| Betina Liliendal | Management | 1 company |
Frequently asked questions
What is the CVR number of Teva Denmark A/S?
Teva Denmark A/S is registered with CVR / Virk under CVR 29634076.
What is the revenue of Teva Denmark A/S?
Teva Denmark A/S reported revenue of DKK 645.3m in 2025.
How many employees does Teva Denmark A/S have?
Teva Denmark A/S employs 38 people as of the latest annual report.
Who is the CEO of Teva Denmark A/S?
Morten Nielsen is the CEO of Teva Denmark A/S, in role since 2019.
Where is Teva Denmark A/S headquartered?
Teva Denmark A/S's registered address is Vandtårnsvej 83A.